Is it ethical to keep interim findings of randomised controlled trials confidential?

Data monitoring committees often are employed to review interim findings of randomised controlled trials. Interim findings are kept confidential until the data monitoring committee finds that they provide sufficiently compelling evidence regarding efficacy, typically because they have crossed the pr...

Full description

Saved in:  
Bibliographic Details
Authors: Miller, F. G. (Author) ; Wendler, D. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2008
In: Journal of medical ethics
Year: 2008, Volume: 34, Issue: 3, Pages: 198-201
Online Access: Volltext (JSTOR)
Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000naa a22000002 4500
001 1816134465
003 DE-627
005 20220908053449.0
007 cr uuu---uuuuu
008 220908s2008 xx |||||o 00| ||eng c
024 7 |a 10.1136/jme.2006.019109  |2 doi 
035 |a (DE-627)1816134465 
035 |a (DE-599)KXP1816134465 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Miller, F. G.  |e VerfasserIn  |4 aut 
245 1 0 |a Is it ethical to keep interim findings of randomised controlled trials confidential? 
264 1 |c 2008 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Data monitoring committees often are employed to review interim findings of randomised controlled trials. Interim findings are kept confidential until the data monitoring committee finds that they provide sufficiently compelling evidence regarding efficacy, typically because they have crossed the pre-defined statistical boundaries, or they raise serious concerns about safety. While this practice is vital to maintaining the scientific integrity of controlled trials and thereby ensuring their social value, it has been criticised as unethical. Commentators argue that withholding interim findings from research participants is deceptive, inconsistent with valid informed consent, and a violation of respect for participants’ autonomy. The present article examines these arguments, focusing specifically on confidential data monitoring for efficacy. This practice need not be deceptive provided its use is disclosed to prospective research participants. In addition, confidential data monitoring does not make research participants worse off than they would be in the clinical setting and represents an acceptable limitation on the options available to prospective research participants. Taken together, these considerations suggest confidential data monitoring, subject to adequate safeguards, is ethically acceptable. 
601 |a Controlling 
700 1 |a Wendler, D.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 34(2008), 3, Seite 198-201  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:34  |g year:2008  |g number:3  |g pages:198-201 
856 |3 Volltext  |u http://www.jstor.org/stable/27720040  |x JSTOR 
856 4 0 |u https://doi.org/10.1136/jme.2006.019109  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/34/3/198.abstract  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
936 u w |d 34  |j 2008  |e 3  |h 198-201 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 418558833X 
LOK |0 003 DE-627 
LOK |0 004 1816134465 
LOK |0 005 20220908053449 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-02#82213CA5DE96092CFD0E486004FB8B93A76D29D4 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/27720040 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1  |b inherited from superior work 
ORI |a SA-MARC-ixtheoa001.raw